This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
|Articles|June 2, 2003
- Pharmaceutical Technology-06-02-2003
- Volume 27
- Issue 6
Enhancement of the Dissolution Rate and Bioavailability of Glipizide through Cyclodextrin Inclusion Complex
Author(s)Adel M. Aly, PhD
This study characterized the interaction between glipiide and cyclodextrins and documented the influence of three tablet formulations on the blood glucose levels of mice.
Advertisement
Articles in this issue
over 23 years ago
June 2003over 23 years ago
From Genome Exploration to Drug Developmentover 23 years ago
Are you ready for Gen3over 23 years ago
Formulation Development of a Nucleotide Phosphoramidateover 23 years ago
Outsourcing OutlookAdvertisement
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
France Remains One of Europe’s Leading Biotech Funding Hubs
2
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
3
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
4
Investing in Protecting Pharma Products
5